anonymous
Guest
anonymous
Guest
I’m surprised no one has yet to make post about the 50 mg sample issues. Where are they? How come the sales force was ALWAYS told that Mybertriq “keeps the lights” on for this company. We all know the importance of having samples for our physicians when you’re treating OAB. The cost just for a patient to try 50 mg for a month is not cost effective for them. Samples are a must because this is not a life savings drug that a patient needs to pay for over their BP, cholesterol, diabetes, heart failure etc. So let’s look at the red flag that this raises in the last quarter of the fiscal year that I’m surprised has shown up in this forum. Astellas is struggling. We are not going to hit our number by March 31 and what better way to reduce costs than to eliminate 50 mg samples till April 1. Every mgr you ask about what the issue is you get 10 diff reasons. Has David, (useless) Lisa or Lynn addressed the issue point blank or are they even giving updates on what the time frame is till we get them???. Mark your calendars….not till after April. Meanwhile, during our year end reviews we will have to justify why Gemtesa is taking market share away from us. $$$$$$